Aileen Mcgill

Second Circuit Declares Off-Label Promotion Ban Unconstitutional: Implications for False Claims Act Defendants

On December 3, 2012, the United States Court of Appeals for the Second Circuit held that the First Amendment protects pharmaceutical companies who truthfully promote the lawful, off-label use of prescription drugs from...more

1/17/2013 - Commercial Speech False Claims Act FDA FDCA Fraud Free Speech Marketing Medicare Misbranding Off-Label Promotion Off-Label Use Pharmaceutical Qui Tam Whistleblowers